Neuland Laboratories
Neuland Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Neuland Laboratories
Start SIPNeuland Laboratories Investment Rating
-
Master Rating:
-
Neuland Laboratories has an operating revenue of Rs. 1,040.00 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 9% is okay, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 88 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 269 | 294 | 221 | 256 |
| Operating Expenses Qtr Cr | 215 | 225 | 193 | 217 |
| Operating Profit Qtr Cr | 54 | 69 | 28 | 39 |
| Depreciation Qtr Cr | 13 | 13 | 13 | 12 |
| Interest Qtr Cr | 3 | 3 | 3 | 3 |
| Tax Qtr Cr | 8 | 15 | 3 | 2 |
| Net Profit Qtr Cr | 30 | 38 | 10 | 22 |
Neuland Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 15
- Bearish Moving Average
- ___
- 1
- 20 Day
- 1632.91
- 50 Day
- 1610.07
- 100 Day
- 1576.4
- 200 Day
- 1513.19
- 20 Day
- 1638.62
- 50 Day
- 1583.79
- 100 Day
- 1632.9
- 200 Day
- 1439.92
Neuland Laboratories Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1654.75 |
| Second Resistance | 1670.65 |
| Third Resistance | 1689.5 |
| RSI | 51.93 |
| MFI | 64.46 |
| MACD Single Line | 24.92 |
| MACD | 20.25 |
| Support | |
|---|---|
| First Resistance | 1620 |
| Second Resistance | 1601.15 |
| Third Resistance | 1585.25 |
Neuland Laboratories Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 15,872 | 504,095 | 31.76 |
| Week | 16,459 | 475,342 | 28.88 |
| 1 Month | 29,434 | 1,072,883 | 36.45 |
| 6 Month | 66,571 | 2,102,307 | 31.58 |
Neuland Laboratories Result Highlights
Neuland Laboratories Synopsis
NSE-Medical-Diversified
Neuland Laborat is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 951.08 Cr. and Equity Capital is Rs. 12.90 Cr. for the Year ended 31/03/2022. Neuland Laboratories Ltd. is a Public Limited Listed company incorporated on 07/01/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004393 and registration number is 004393.| Market Cap | 2,125 |
| Sales | 1,040 |
| Shares in Float | 0.82 |
| No of funds | 56 |
| Yield | 0.31 |
| Book Value | 2.53 |
| U/D Vol ratio | 1.9 |
| LTDebt / Equity | 12 |
| Alpha | 0.22 |
| Beta | 0.83 |
Neuland Laboratories
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 36.14% | 36.22% | 36.22% | |
| Mutual Funds | 0.79% | 0.79% | 0.79% | |
| Foreign Portfolio Investors | 17.7% | 17.68% | 17.37% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 30.09% | 31.02% | 33.25% | |
| Others | 15.28% | 14.29% | 12.37% |
Neuland Laboratories Management
| Name | Designation |
|---|---|
| Dr. Davuluri Rama Mohan Rao | Executive Chairman |
| Mr. Davuluri Sucheth Rao | Vice Chairman & CEO |
| Mr. Davuluri Saharsh Rao | Vice Chairman & Mng.Director |
| Dr. Christopher M Cimarusti | Non Executive Director |
| Mr. Humayun Dhanrajgir | Ind. Non-Executive Director |
| Mrs. Bharati Rao | Ind. Non-Executive Director |
| Dr. Nirmala Murthy | Ind. Non-Executive Director |
| Mr. Parampally Vasudeva Maiya | Ind. Non-Executive Director |
| Mr. Homi Rustum Khusrokhan | Ind. Non-Executive Director |
Neuland Laboratories Forecast
Price Estimates
Neuland Laboratories FAQs
What is Share Price of Neuland Laboratories ?
Neuland Laboratories share price is ₹1657 As on 22 March, 2023 | 11:06
What is the Market Cap of Neuland Laboratories ?
The Market Cap of Neuland Laboratories is ₹2127.1 Cr As on 22 March, 2023 | 11:06
What is the P/E ratio of Neuland Laboratories ?
The P/E ratio of Neuland Laboratories is 21.1 As on 22 March, 2023 | 11:06
What is the PB ratio of Neuland Laboratories ?
The PB ratio of Neuland Laboratories is 2.5 As on 22 March, 2023 | 11:06